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Spinal anesthesiaAbstract Introduction: Shivering is one of the most common complications of neuraxial blockade.
Some patients ﬁnd shivering sensation worse than surgical pain. Therefore, both prevention and
treatment of established shivering should be regarded as clinically relevant intervention in the per-
ioperative period. The aim of our study is to compare the efﬁcacy of magnesium sulfate when used
for prevention or treatment of shivering following spinal anesthesia.
Methods: In this prospective, double blind, placebo controlled study, 120 ASA I, II patients under-
going surgery under spinal anesthesia were randomized into 3 groups. Following intrathecal injec-
tion, Group P (prophylactic) was given MgSO4, 50 mg/kg I.V. bolus + 2 mg/kg/h infusion. Group
T (therapeutic) was given MgSO4 50 mg/kg I.V. bolus as a therapy when shivering occurred. If shiv-
ering persisted, they received 25 mg/kg I.V. bolus. Group C (control) received saline at identical
times. Meperidine was given as rescue if shivering persisted. Shivering grade 3/4 was regarded as
signiﬁcant. Core temperatures, incidence of shivering, and side effects were recorded.
Main results: Total incidence of shivering, grade 3/4, was 15% in Group P, 45% in Group T, and
50% in Group C (p< 0.01). Magnesium sulfate signiﬁcantly reduced the incidence and gain of
shivering. The use of rescue meperidine was more in Group P (20%) and Group C (50%) compared
to none in Group T (p< 0.05, p< 0.01, respectively). Signiﬁcant reduction in core temperature
occurred in the Mg groups compared to the control group p< 0.05. No correlation was found
between patients who shivered and core temperature or DT. Hypotension was more frequent in
Group P; nausea and vomiting were more in Mg groups than control group p< 0.05.
32 I.T. Ibrahim et al.Conclusion: Following spinal anesthesia, prophylactic MgSO4 infusion lowered incidence of shiv-
ering. When shivering did occur, MgSO4 proved to be an effective treatment with minimal side
effects.
ª 2013 Production and hosting by Elsevier B.V. on behalf of Egyptian Society of Anesthesiologists.1. Introduction
Shivering is a frequent complication following neuraxial anes-
thesia. It is an involuntary, oscillatory muscular activity that
augments metabolic heat production. Shivering may occur as
a response to hypothermia. However, it may also occur in nor-
mothermic patients [1].
Regional anesthesia impairs both central and peripheral
thermoregulatory control. In patients becoming sufﬁciently
hypothermic, shivering may appear and is often disturbing to
both patients and medical staff [2]. Shivering may interfere
with monitoring of heart rate, blood pressure, and oxygen sat-
uration. It is associated with substantial adrenergic activation
[3]. It increases oxygen consumption, lactic acidosis, carbon
dioxide production, and metabolic rate by up to 400%; thus,
it may cause problems in patients with low cardiac and pul-
monary reserves [1].
Numerous studies have tested the efﬁcacy of a large variety
of interventions to prevent shivering in normothermic or hypo-
thermic surgical patients, but the relative efﬁcacy of these
interventions, however, remains unclear [4].
As the incidence of hypotension is high during regional
anesthesia, hypotensive agents including clonidine and urapidil
may not be appropriate in preventing shivering. In addition,
meperidine (the most widely used agent) and tramadol may
cause nausea and vomiting and respiratory depression during
and after regional anesthesia. The hypertensive and tachycar-
diac effects of ketamine limits its use [5].
The search continues for drugs that sufﬁciently improve
thermoregulatory tolerance without simultaneously producing
excessive sedation or respiratory depression.
Intravenous magnesium has been shown to suppress post-
operative shivering suggesting that the agent reduces the shiv-
ering threshold [6]. Recently, the addition of intravenous
magnesium sulfate to a pharmacological antishivering regimen
increased the cooling rate in unanesthetized volunteers [7]. The
drug not only exerts a central effect [8] but is also a mild mus-
cle relaxant [9] and may thus simultaneously reduce the gain of
shivering (incremental shivering intensity with progressing
hypothermia) [10].
This study was designed to compare the effectiveness of
magnesium sulfate when given prophylactically to that given
as treatment in the control of shivering.2. Patients and methods
This randomized, double blind, placebo controlled study was
carried out at the anesthesiology department in El-Minia Uni-
versity Hospital. We included 120 male and female patients,
18–60 years of age scheduled to undergo elective lower extra-
peritoneal abdominal or lower limb surgery using spinal anes-
thesia. Patients with ASA physical status > II, severe
cardiopulmonary disease, renal or liver impairment, preopera-
tive fever, history of seizures or peripheral neurologicaldisease, contraindication to regional anesthesia, thyroid dis-
ease, parkinsonism, Raynaud’s syndrome, allergy to the study
medications, massive blood transfusion during surgery and
those receiving vasodilators or medications that alter thermo-
regulation were excluded from the study.
The study was double blind (neither the investigator nor the
patients knew the nature of the drugs given), and the unknown
solutions were prepared and supplied to the investigator in
25 ml ampoules and coded as (A, B, C and D) for IV injection
and infusion. The protocol was opened after the study was
completed.
Randomization was done according to computer generated
number.
The study drugs were administered as follows:
 0.5 ml / kg was taken from ampoule A, diluted in 60 ml glu-
cose 5% and injected IV over 10 min immediately after
spinal injection.
 This is followed by 2 ml taken from ampoule B, diluted in
200 ml and given IV at a rate of 2 ml/kg/h.
 If shivering occurs, 0.5 ml/kg was taken from ampoule C,
diluted in 60 ml glucose 5%, and injected IV over 10 min.
 If shivering continues, 0.25 ml/kg was taken from ampoule
D, diluted to 60 ml glucose 5%, and injected IV over
10 min.
 If shivering persists, meperidine 25 mg was injected IV.
Drugs used in the study were the following: magnesium sul-
fate ampoule 25 ml 10%, 100 mg/ ml (Egypt Otsuka pharm.
Co.); saline 0.9% ampoule 25 ml (Egypt Otsuka pharm.
Co.); and meperidine (Pethidine) 50 mg/ml.
The patients admitted were blindly injected and classiﬁed
into 3 equal groups (40 patients each), group P (Prophylactic
group), received MgSO4 50 mg/kg IV bolus + 2 mg/kg/h infu-
sion as prophylaxis (A and B ampoules were MgSO4 and C
and D ampoules were saline), Group T (Therapeutic group):
received MgSO4 50 mg/kg IV bolus as therapy when shivering
occurred, and if shivering persists, they received 25 mg/kg IV
bolus of MgSO4 (A and B ampoules were saline; C and D am-
poules were MgSO4) and group C (Control group) received
0.9% saline for injection as a placebo (A, B, C, and D am-
poules were saline). In all groups if shivering of grade 3 or
more persists, meperidine 25 mg IV was given as a rescue drug.
No premedication was given. In the operating room, after
IV access, all patients received 500 cc lactated Ringer’s solu-
tion maintained at room temperature. The ambient tempera-
ture was maintained at 22–24 C.
Spinal anesthesia was performed at either L3/4 or L4/5
interspaces. Hyperbaric bupivacaine, 20 mg was injected using
a 24 gauge spinal needle with the patients in the lateral decubi-
tus position. Level of sensory blockade was assessed by pin-
prick and motor blockade by Bromage scale [11].
Supplemental oxygen was delivered via a nasal cannula
(4 L/min) if needed. Intraoperatively, all patients were moni-
tored and covered by one layer of surgical drapes.
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ature were measured by Advisor monitors (Smith Medical PM,
Inc., Waukesha, WL, 53186). These parameters were recorded
preoperative, after induction of anesthesia, every 10 min till
the end of surgery, then every 10 min postoperative until 2 seg-
ments regression of the sensory blockade.
Tympanic (core) temperature was measured by an ear ther-
mometer. The aural probe was inserted until the patient felt it
touching the tympanic membrane, the probe was then securely
taped in place, and the aural canal was occluded with cotton
and a gauze bandage was positioned over the external ear. Ax-
illary (skin) temperature was measured by an axillary ther-
mometer. Temperature difference was measured (DT= core
temperature  skin temperature). Core temperature less than
36 C was considered hypothermia.
Shivering was assessed after completion of subarachnoid
injection until the patient was discharged after 2 segments
regression of sensory blockade by a scale similar to that val-
idated by Crossley and Mahajan [12] which is 0 = No shiver-
ing, 1 = Cyanosis and piloerection, 2 = Visible tremors only
in one muscle group, 3 = Visible tremors in more than one
muscle group, and 4 = Intense shivering, tremors of the
head, arm. Side effects like hypotension, nausea and vomit-
ing, respiratory depression, and diminished deep tendon re-
ﬂexes in upper extremities were recorded. Hypotension was
treated by crystalloid infusion and if necessary IV ephedrine
5 mg. Nausea and vomiting was treated by IV metoclopra-
mide 10 mg. Postoperatively, all patients were transferred to
postoperative care unit (PACU) and monitored every
10 min until discharge.
2.1. Statistical analysis
Data were analyzed by using SPSS (The Statistical Package for
Social Sciences) version 17.0 software. Categorical data includ-
ing total incidence of shivering and side effects were analyzed
using Chi square. Independent t-test was used for quantitative
data for comparison between two groups; paired t-test, for
quantitative data within each group; one-way ANOVA, for
quantitative data comparison between the 3 groups; Fisher’s
exact test, for categorical data between the study groups;
Mann Whitney test, for quantitative nonparametric data be-
tween two groups; Kruskal–Wallis H-test, for quantitative
nonparametric data between three groups; and Spearman cor-
relation for correlation testing.Table 1 Demographic data and type of operation in the study gro
Data Group
Prophylactic n= 40
Age (yrs) 30.9 ± 11
Weight (kg) 73 ± 10.1
Sex males: n (%) 38 (95%)
Females: n (%) 2 (5%)
Type of operation
General surgery: n (%) 16 (40%)
Orthopedic: n (%) 18 (45%)
Urologic: n (%) 6 (15%)
Data are presented as Mean ± SD. n= number.P-value 6 0.05 was considered signiﬁcant.
3. Results
A total of 120 patients completed this study, 40 in each group.
The three groups were similar as regards age, weight, height,
and ASA physical status (Table 1). They were also comparable
in duration of anesthesia, surgery, and amount of crystalloid
administered. Total dose of magnesium sulfate was signiﬁ-
cantly higher in Group P (3863 ± 544 mg) vs. (2425 ±
1941.8 mg) in Group T (p< 0.05) (Table 2).
There was insigniﬁcant change as regards mean heart rate,
mean arterial blood pressure, oxygen saturation, and mean
respiratory rate in the three groups throughout the study
period.
Hypothermia occurred in MgSO4 groups with respect to
baseline temperature. Hypothermia began earlier in group P,
10 min after induction of spinal anesthesia compared to group
T, after 20 min. Degree of hypothermia was greater in Group P
than Group T. Also, reduction in tympanic membrane temper-
ature was signiﬁcantly greater in the Mg groups compared to
the control group (P< 0.01). After receiving spinal anesthesia
until 80 min, the core temperature was signiﬁcantly lower in
Group P than Group C (p< 0.01), from 20 to 60 min the core
temperature was signiﬁcantly lower in Group T than Group C
(p< 0.05) (Fig. 1). There was no correlation between patients
who shivered and core temperature (Table 3 and Fig. 3) or DT
(DT= core  skin temperature) (Table 4).
Total incidence of shivering grade 3/4 was 15% in Group P,
45% in Group T, and 50% in Group C. Shivering was consid-
ered signiﬁcant when the patient shivered at least to grade 3
[12]. Ten min after induction of spinal anesthesia, correspond-
ing to the end of the bolus dose of MgSO4 in Group P, only
5% had shivering grade 3/4 compared to 25% in Group T
and 35% in Group C. Up to 40 min, there was signiﬁcant dif-
ference in incidence of shivering between the 3 groups, being
more in Groups T and C than Group P (Fig. 2). In the thera-
peutic group, a single dose of MgSO4 was effective in control-
ling shivering as only 4 patients (20%) of the 18 patients who
shivered required a second dose of Mg. Prophylactic MgSO4
was effective in reducing the incidence of shivering, but when
shivering occurred, therapeutic Mg was more effective in the
control of shivering as evidenced by the use of rescue meperi-
dine which was more in Group P (20%) and Group C (50%)
compared to none in Group T (p< 0.05, p< 0.01,ups.
Therapeutic n= 40 Control n= 40
31.6 ± 11.4 30 ± 10.4
70.5 ± 12.7 73 ± 9.2
32 (80%) 34 (85%)
8 (20%) 6 (15%)
12 (30%) 12 (30%)
20 (50%) 22 (55%)
8 (20%) 6 (15%)
Table 2 Operative data.
Data Group
Prophylactic n= 40 Therapeutic n= 40 Control n= 40
Anesthetic duration (min) 85.5 ± 17 81.5 ± 14.6 86 ± 18.2
Surgical duration (min) 61 ± 16 59.3 ± 13.9 62.75 ± 18.3
Crystalloid ﬂuids (cc) 1550 ± 426.1 1325 ± 372.6 1553 ± 535.6
Drug administration
None: n (%) 26 (70%) 34 (85%) 34 (85%)
Atropine: n (%) 0 (0%) 0 (0%) 2 (5%)
Ephedrine: n (%) 6 (15%) 0 (0%) 2 (5%)
Metoclopramide: n (%) 8 (20%) 6 (15%) 2 (5%)
Meperidine use: n (%) 8 (20%)* 0 (0%) 20 (50%) **
Total dose Mg (mg) 3863 ± 544* 2425 ± 1941.8 0
Data are presented as Mean ± SD, n= number.
* p< 0.05 Group P vs. Group T.
** p< 0.01 Group C vs. Group T.
Figure 1 Changes in mean core temperature in the three groups.
Figure 2 Changes in incidence of shivering grade 3/4 over time.
34 I.T. Ibrahim et al.respectively). Hypotension occurred in 6(15%) in Group P and
2(5%) in Group C and none in Group T. Nausea and vomiting
occurred in 8(20%) in Group P, 6(15%) in Group T, and
2(5%) in Group C (Table 5).
4. Discussion
Postanesthesia shivering is very common following neuroaxial
anesthesia. In our study, shivering was reported in 45–50% of
patients in the control and therapeutic groups similar to 57%
incidence reported in earlier studies [13].The exact mechanism of shivering during regional anesthe-
sia has not been fully established. Postanesthesia shivering is
probably a combination of both thermoregulatory and non-
thermoregulatory shivering [1]. Thermoregulatory shivering
is a response to hypothermia due to redistribution of body heat
from the core to the periphery [14]. The resultant vasoconstric-
tion and shivering are restricted to the upper body due to the
sympathetic and somatic neural blockade below the level of
spinal blockade [15].
In our study, we found that postspinal shivering may ap-
pear within minutes after injection of local anesthetic and
long before sufﬁcient time has elapsed for signiﬁcant heat loss
to have occurred; therefore, other mechanisms of shivering
exist. The same ﬁnding led Bromage [11] to postulate that
spinal cord response is secondary to misinterpretation of
afferent thermal clues due to differential blockade of warm
and cold sensation, which is also supported by Kaoy et al.
[16].
Also, shivering has been reported in normothermic pa-
tients, suggesting that inhibited spinal reﬂexes, apprehension,
decreased sympathetic activity, pyrogen release, adrenal gland
suppression, and respiratory alkalosis are also involved [17].
A wide variety of agents with different mechanisms of ac-
tion including opioids, nonopioid analgesics, 5-HT3 antago-
nists, a2 adrenoreceptor agonists, and cholinomimetic agents
have been studied in an attempt to prevent or treat shivering,
but unfortunately, there is no ‘‘gold-standard’’ drug for the
Figure 3 Correlation between core temperature and shivering.
Table 3 Correlation between incidence of shivering and core temperature.
Period Group
Group P Group T Group C
Shiv
grade 3/4 (%)
Core
temp M± SD
r P Shiv
grade 3/4 (%)
Core
temp M± SD
r p Shiv
grade 3/4 (%)
Core
temp M± SD
r p
After induction 10 36.2 ± 0.3 0.53 0.17 15 37.1 ± 0.5 0.19 0.41 30 37.3 ± 0.4 0.18 0.46
After 10 min 5 35.8 ± 0.3 0.36 0.13 25 37 ± 0.4 0.24 0.29 35 37.1 ± 0.4 0.12 0.61
After 20 min 0 35.7 ± 0.4 0.29 0.21 25 35.7 ± 0.4 0.3 0.2 45 36.9 ± 0.4 0.19 0.43
After 30 min 0 35.5 ± 0.3 0.22 0.35 15 35.6 ± 0.4 0.38 0.1 45 36.7 ± 0.4 0.17 0.46
After 40 min 5 35.3 ± 0.3 0.19 0.41 15 35.4 ± 0.35 0.1 0.69 45 36.7 ± 0.5 0.13 0.58
After 50 min 10 35.2 ± 0.4 0.13 0.26 0 35.3 ± 0.37 0.01 0.99 15 36.6 ± 0.4 0.16 0.77
After 60 min 0 35.2 ± 0.3 0.54 0.08 0 35.5 ± 0.3 0.02 0.94 10 36.6 ± 0.3 0.16 0.62
After 70 min 0 35.5 ± 0.5 0.43 0.34 0 36.1 ± 0.4 0.01 0.99 10 36.3 ± 0.3 0.13 0.72
Spearman correlation, for nonparametric quantitative data. Shiv (%): Incidence of shivering by percentage. Core temp: Core temperature.
M± SD: mean ± standard deviation. r: Correlation coefﬁcient. p: p-value.
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drugs that sufﬁciently reduce the shivering threshold and im-
prove thermoregulatory tolerance without simultaneously pro-
ducing excessive sedation or respiratory depression [4].
Magnesium is a naturally occurring calcium competitor
and a noncompetitive antagonist of N-methyl-D-aspartate
(NMDA) receptors [18]. The exact protective mechanism of
MgSO4 remains uncertain; Magnesium prevents or controls
convulsions by blocking neuromuscular transmission andTable 4 Correlation between DT measurements and incidence of sh
Period Group
Group P Group T
Shiv (%) DT M± SD r p Shiv (%) D
After induction 10 0.67 ± 0.24 0.03 0.9 15 0
After 10 min 5 0.62 ± 0.2 0.11 0.66 25 0
After 20 min 0 0.59 ± 0.2 0.27 0.25 25
After 30 min 0 0.55 ± 0.24 0.31 0.19 15 0
After 40 min 5 0.51 ± 0.27 0.27 0.25 15 0
After 50 min 10 0.51 ± 0.16 0.31 0.19 0 0
After 60 min 0 0.52 ± 0.2 0.14 0.58 0 0
After 70 min 0 0.53 ± 0.18 0.08 0.87 0 0
Spearman correlation, for nonparametric quantitative data. Shiv (%): In
relation coefﬁcient. M± SD: mean ± standard deviation. p: p-value.decreasing the release of acetylcholine at the motor nerve ter-
minals [19]. Parenteral magnesium sulfate is the drug of
choice for the prevention and treatment of eclamptic convul-
sions [20]. It is an effective treatment for postoperative shiv-
ering following general anesthesia [6]. Magnesium has been
reported to reduce shivering threshold in healthy volunteers
[21], as treatments that reduce the shivering threshold by a
few tenths of a degree Celsius may be sufﬁcient to attenuate
postoperative shivering [22]. In our study, core hypothermia
occurred in all Mg groups being more evident in the prophy-
lactic group than the therapeutic group. It is likely that larger
doses of MgSO4 would produce greater thermoregulatory ef-
fects but carries a greater risk of complications as the ther-
moregulatory response to most IV drugs is linear with
plasma concentration [23].
Patients receiving prophylactic magnesium in our study had
a lower incidence of shivering than the other groups. This is
due to its mild muscle relaxant effect, thereby reducing the gain
of shivering (incremental shivering intensity with progressing
hypothermia). Magnesium has been suggested as a possible
means of resolving muscle rigidity and spasm in tetanus [24].
An earlier study by Gozedemir et al., achieved a lower inci-
dence of shivering 6.7% compared to 15% in our study. This is
probably due to the higher dose of magnesium in their study
8.6 g (80 mg/kg bolus then 2 g/h) compared to 3.9 ± 0.54 givering.
Group C
T M± SD r p Shiv (%) DT M± SD r p
.76 ± 0.24 0.06 0.93 30 0.78 ± 0.22 0.09 0.73
.75 ± 0.27 0.26 0.27 35 0.77 ± 0.28 0.12 0.68
0.6 ± 0.2 0.3 0.2 45 0.74 ± 0.22 0.2 0.41
.58 ± 0.2 0.24 0.32 45 0.73 ± 0.24 0.22 0.34
.55 ± 0.2 0.12 0.68 45 0.72 ± 0.24 0.25 0.3
.54 ± 0.1 0.01 0.99 15 0.7 ± 0.23 0.26 0.28
.57 ± 0.1 0.02 0.94 10 0.68 ± 0.2 0.18 0.61
.61 ± 0.1 0.01 0.99 10 0.64 ± 0.2 0.14 0.72
cidence of shivering grade 3/4. DT: Temperature difference. r: Cor-
Table 5 Complications during the study period.
Side eﬀects Group
Prophylactic (P) n= 40 Therapeutic (T) n= 40 Control (C) n= 40 p Value
n (%) n (%) n (%) P vs. T P vs. C T vs. C
Absent 26 (65%) 34 (85%) 34 (85%) 0.2 0.2 1
Bradycardia 0 (0%) 0 (0%) 2 (5%) – 0.3 0.3
Hypotension 6 (15%) 0 (0%) 2 (5%) 0.2 0.6 0.3
Nausea and vomiting 8 (20%) 6 (15%) 2 (5%) 0.9 0.3 0.6
n= number. No signiﬁcant difference between the 3 groups.
36 I.T. Ibrahim et al.in our study [25]. Kizilirmak et al., used 30 mg/kg bolus as the
treatment for postoperative shivering following general anesthe-
sia and found that it was as effective as meperidine but meper-
idine stopped shivering slightly faster than magnesium [6].
We found no correlation between incidence of shivering
and core temperature, and this ﬁnding is supported by the re-
view of ﬁfteen trials by Kranke et al., who found no relation-
ship between shivering and average core temperature [4].
Minor side effects as hypotension, nausea, and vomiting
were more frequent in the prophylactic group but not statisti-
cally signiﬁcant. Cumulative data from 8 studies showed nau-
sea, arterial hypotension, and bradycardia occurred more
often with magnesium. None of the differences, however,
was statistically signiﬁcant [26]. Hypotension is due to the
vasodilating effect of MgSO4. This property was used by
Ryu et al., to induce controlled hypotension in middle ear sur-
gery [27] and also reduce blood loss during endoscopic sinus
surgery [28].
From our study, we can conclude that following spinal
anesthesia, prophylactic MgSO4 infusion lowered incidence
of shivering. It also proved to be an effective treatment when
postspinal shivering occurred with minimal side effects.
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